Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography.
Hannah E GreenwoodPatrick N McCormickThibault GendronMatthias GlaserRaul PereiraOliver D K MaddocksKerstin SanderTong ZhangNorman KoglinMark F LythgoeErik ÅrstadDaniel HochhauserTimothy H WitneyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This study demonstrates the ability of [18F]FSPG to detect upregulated antioxidant pathways present in drug-resistant cancer. [18F]FSPG may therefore enable the identification of patients with HGSOC that are refractory to standard of care, allowing the transferal of drug-resistant patients to alternative therapies, thereby improving outcomes in this disease.
Keyphrases
- drug resistant
- positron emission tomography
- multidrug resistant
- acinetobacter baumannii
- computed tomography
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- palliative care
- peritoneal dialysis
- pet imaging
- oxidative stress
- papillary thyroid
- pet ct
- cell therapy
- pseudomonas aeruginosa
- skeletal muscle
- chronic pain
- health insurance
- lymph node metastasis